Patents by Inventor Chengde Wu

Chengde Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds as rearranged during transfection (RET) inhibitors
    Patent number: 8937071
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 20, 2015
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Hilary Schenck Eidam, Kaushik Raha, Zhen Gong, Huiping Amy Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui Cheung
  • NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
    Publication number: 20140275111
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Hilary Schenck EIDAM, Kaushik Raha, Zhen Gong, Huiping Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui CHEUNG
  • BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS
    Publication number: 20120083489
    Abstract: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.
    Type: Application
    Filed: June 2, 2010
    Publication date: April 5, 2012
    Inventors: Siegfried Benjamin Christensen IV, Donghui Qin, Shenglin Chen, Xing Huang, Di Li, Fei Li, Lei Li, Xiaojuan Lin, Shi Lu, Zhen Lu, Maoyun Lv, Chuanning Wang, Chengde Wu, Mei Xiao, Haiyu Yu, Weina Zhang, Zhiliu Zhang
  • BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS
    Publication number: 20120077794
    Abstract: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.
    Type: Application
    Filed: June 2, 2010
    Publication date: March 29, 2012
    Applicant: GLAXSMITHKLINE LLC
    Inventors: Siegfried Benjamin Christensen, IV, Donghui Qin, Shenglin Chen, Xing Huang, Di Li, Fei Li, Xiaojuan Lin, Shi Lu, Maoyun Lv, Chengde Wu, Weiliang Xu, Gang Yan, Jianxing Yuan, Weina Zhang, Zhiliu Zhang
  • Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
    Patent number: 7812038
    Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: October 12, 2010
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Ronald J. Biediger, Qi Chen, E. Radford Decker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Ian L. Scott, Chengde Wu, Jian Li
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Patent number: 7579340
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: August 25, 2009
    Assignee: Pfizer Inc
    Inventors: Ronald Biediger, Jie Chen, Daxin Gao, Robert Market, Chengde Wu
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Patent number: 7320989
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: January 22, 2008
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Brian Dupre, Daxin Gao, Raymond J. Kessler, Wen Li, Chengde Wu
  • Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
    Patent number: 7319111
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: January 15, 2008
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Daxin Gao, Robert Market, Chengde Wu
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Publication number: 20080004312
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: May 25, 2007
    Publication date: January 3, 2008
    Inventors: Eric Anderson, Brian Dupre, Daxin Gao, Raymond Kessler, Wen Li, Chengde Wu
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Publication number: 20070293503
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: August 22, 2007
    Publication date: December 20, 2007
    Inventors: Ronald Biediger, Jie Chen, Daxin Gao, Robert Market, Chengde Wu
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Patent number: 7288538
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: October 30, 2007
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Chengde Wu, Daxin Gao, Ronald Biediger, Jie Chen, Robert V. Market
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Patent number: 7265122
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: September 4, 2007
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Chengde Wu, C. Eric Anderson, Huong Bui, Brian Dupre, Daxin Gao, George W. Holland, Jamal Kassir, Wen Li, Junmei Wang
  • Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
    Publication number: 20060276476
    Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Application
    Filed: June 14, 2005
    Publication date: December 7, 2006
    Inventors: Ronald Biediger, Qi Chen, E. Decker, George Holland, Jamal Kassir, Wen Li, Robert Market, Ian Scott, Chengde Wu, Jian Li
  • Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
    Patent number: 6972296
    Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: December 6, 2005
    Assignee: Encysive Pharmaceuticals Inc.
    Inventors: Ronald J. Biediger, Qi Chen, E. Radford Decker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Ian L. Scott, Chengde Wu, Jian Li
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Publication number: 20050054850
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: August 23, 2004
    Publication date: March 10, 2005
    Inventors: Chengde Wu, C. Anderson, Huong Bui, Brian Dupre, Daxin Gao, George Holland, Jamal Kassir, Wen Li, Junmei Wang
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Publication number: 20050049286
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: August 23, 2004
    Publication date: March 3, 2005
    Inventors: Chengde Wu, C. Anderson, Huong Bui, Daxin Gao, Jamal Kassir, Wen Li, Junmei Wang, Ronald Biediger, Jie Chen, Robert Market
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Publication number: 20040186102
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: February 20, 2004
    Publication date: September 23, 2004
    Inventors: Chengde Wu, C. Eric Anderson, Huong Bui, Brian Dupre, Daxin Gao, George W. Holland, Jamal Kassir, Wen Li, Junmei Wang
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Publication number: 20040180892
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: February 18, 2004
    Publication date: September 16, 2004
    Applicant: Encysive Pharmaceuticals Inc.
    Inventors: Chengde Wu, C. Eric Anderson, Huong Bui, Daxin Gao, Jamal Kassir, Wen Li, Junmei Wang, Robert V. Market
  • Propanoic acid derivatives that inhibit the binding of integrins to their receptors
    Patent number: 6723711
    Abstract: A compound of the structure A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1(vascular cell adhesion molecule-1) and fibronectin; pharmaceutically active compositions comprising these compounds; and the use of these compounds for the control or prevention of diseases states in which &agr;4&bgr;1 is involved are also disclosed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: April 20, 2004
    Assignee: Texas Biotechnology Corporation
    Inventors: Ronald J. Biediger, Brian Dupre, Linda K. Hamaker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Noel Nguyen, Ian L. Scott, Chengde Wu, E. Radford Decker
  • Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
    Publication number: 20040063955
    Abstract: A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which &agr;4&bgr;1 is involved.
    Type: Application
    Filed: October 9, 2001
    Publication date: April 1, 2004
    Inventors: Ronald J. Biediger, Qi Chen, E. Radford Decker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Ian L. Scott, Chengde Wu, Jian Li